Welcome Guest | Register / Login

Global Phosphate Binder (Hyperphosphatemia) Market: Industry Analysis & Outlook (2019-2023)

Table of Contents

1. Market Overview
1.1 Chronic Kidney Disease (CKD)
1.2 Hyperphosphatemia
1.3 Phosphate Binder
1.4 Phosphate Binder Products

2. Global Phosphate Binder Market
2.1 Global Phosphate Binders Drugs in Development
2.2 Global Phosphate Binder Prescription Market Share
2.3 Global Sevelamer Revenue
2.4 Global Sevelamer Prescription Market Share by Brand
2.5 Auryxia Prescription and Tablets Count
2.6 Global Velphora Revenue Forecast

3. Regional Markets
3.1 The U.S.
3.1.1 The U.S. Dialysis Patients on Phosphate Binder Forecast
3.1.2 The U.S. Peritoneal Dialysis Patients on Phosphate Binder Forecast
3.1.3 The U.S. Auryxia Revenue and Penetration Forecast
3.1.4 The U.S. Velphoro Revenue Forecast
3.2 Europe
3.2.1 Europe Phosphate Binder Treated Population Forecast
3.2.2 Europe Velphoro Revenue Forecast
3.3 Japan
3.3.1 Japan Phosphate Binder Treated Population Forecast
3.3.2 Japan Velphoro Revenue Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Rising Aging Population
4.1.2 Increasing Healthcare Spending
4.1.3 Increasing Cases of ESRD
4.1.4 Increasing Life Expectancy
4.1.5 High Unmet Medical Needs
4.2 Key Trends & Developments
4.2.1 Increasing Demand for Effective Phosphate Binder Treatment
4.3 Challenges
4.3.1 Gastrointestinal Reactions Leading to Discontinuation
4.3.2 Entry of Generic Products
4.3.3 Regulatory Framework

5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue and Market Cap Comparison
5.1.2 Research & Development Expenditure (as a % of Revenue) Comparison
5.1.3 Approved Phosphate Binders Dosage Comparison
5.1.4 Approved Phosphate Binders Safety Comparison
5.1.5 Approved Phosphate Binders Shortcomings Comparison

6. Company Profiles
6.1 AMAG Pharmaceuticals, Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Vifor Pharma Ltd.
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Sanofi S.A.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Akebia Therapeutics Inc.
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies

List of Tables

Stages of CKD
Renoprotective Strategies for Slowing Progression of CKD
Phosphate Management in Chronic Kidney Disease
Administration of Currently Approved Phosphate Binders
Key Players - Revenue & Market Cap Comparison (2018)
Approved Phosphate Binders Dosage Comparison (2018)
Approved Phosphate Binders Safety Comparison (2018)
Approved Phosphate Binders Shortcomings Comparison (2018)

List of Figures

Types of Phosphate Binders
Global Phosphate Binders Drugs in Development (2018)
Global Phosphate Binder Prescription Market Share (Dec 2017- May 2018)
Global Sevelamer Revenue (2014-2018)
Global Sevelamer Prescription Market Share by Brand (Dec 2017- May 2018)
Auryxia Prescription and Tablets Count (Jan 2017-Apr 2018)
Global Velphora Revenue Forecast (2018-2023)
The U.S. Dialysis Patients on Phosphate Binder Forecast (2018-2023)
The U.S. Peritoneal Dialysis Patients on Phosphate Binder Forecast (2018-2023)
The U.S. Auryxia Revenue and Penetration Forecast (2018-2023)
The U.S. Velphoro Revenue Forecast (2018-2023)
Europe Phosphate Binder Treated Population Forecast (2018-2023)
Europe Velphoro Revenue Forecast (2018-2023)
Japan Phosphate Binder Treated Population Forecast (2018-2023)
Japan Velphoro Revenue Forecast (2018-2023)
Global Aging Population (2014-2018)
Global Healthcare Spending Per Capita (2014-2018)
Global ESRD Patients (2014-2018)
Life Expectancy at Birth (2014-2018)
Phosphate Binder HD Share Over Time (Q1 2017-Q4 2018)
Reasons for Brand Discontinuation (Q1 2019)
Key Players - Research & Development Expenditure (%) Comparison (2018)
AMAG Pharmaceuticals, Inc. Revenue by Segment (2018)
AMAG Pharmaceuticals, Inc. Revenue and Net Income (2014-2018)
AMAG Pharmaceuticals, Inc. R&D Expenditure (2016-2018)
Vifor Pharma Net Sales by Product Brand (2018)
Vifor Pharma Net Sales and Net Profit (2014-2018)
Vifor Pharma R&D Expenditure (2016-2018)
Sanofi S.A. Net Sales by Segment (2018)
Sanofi S.A. Net Sales and Net Income (2014-2018)
Sanofi S.A. R&D Expenditure (2016-2018)
Akebia Therapeutics Inc. Revenue and Net Loss (2014-2018)
Akebia Therapeutics Inc. R&D Expenditure (2016-2018)

Single User License: Report will be emailed in PDF format and can be accessed by a specific user. This License type allows the report to be Printed.
Corporate User License: Report will be emailed in PDF format and allows all employees within the organization to access it. This License type allows the report to be Printed.
Hard Copy: A printed copy of the report will be shipped.      This License type allows the report to be Printed.
Why http://www.marketreportsonline.com/
Published By :Koncept Analytics
Price
We use cookies to deliver the best possible experience on our website.
By continuing to use this site, or closing this box, you consent to our use of cookies. To learn more, visit our Privacy Policy